EBE-A22 is a derivative of PD 153035 which can inhibit ErbB-1-phosphorylation, whereas EBE-A22 is inactive.

NIH-12848 is a specific PI5P4Kγ inhibitor with an IC50 of approximately 1 μM but does not inhibit the α and β PI5P4K isoforms at concentrations up to 100 μM.

Kobe2602 is a selective Ras inhibitor that blocks H-Ras GTP binding to c-Raf-1 (Ki = 149 µM).

RIPA-56 is a highly-potent, selective, and metabolically stable RIP1 (RIPK1) inhibitor.

Danirixin (GSK1325756) is a small molecule, non-peptide, high affinity (IC50 for CXCL8 (IL-8) binding = 12.5 nM), selective, and reversible CXCR2 antagonist.

YL-109 is a novel antitumor agent that has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo.

CDD3505 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity.

AR7 is a retinoic acid receptor α (RARα) antagonist.

AR7 is a retinoic acid receptor α (RARα) antagonist.

TB5 is a potent and selective MAO-B inhibitor with Ki values of 110 and 1,450 nM for MAO-B and MAO-A, respectively.